STERIS plc STE is making its largest-ever investment in a single manufacturing site with a $600 million formulated chemistries Center of Excellence in North Carolina. The project is designed to expand capacity, improve efficiency and support long-term demand across key parts of its portfolio.
The opportunity is meaningful, but so is the execution burden. Investors must weigh potential benefits from scale and automation against higher capital spending, restructuring costs and existing operating pressures.
Year to date, STERIS shares have lost 7% compared with a 6% decline for the industry.
Image Source: Zacks Investment Research
STERIS Commits $600 Million to Chemistry Capacity
The new center will combine manufacturing, research and development, and distribution for formulated chemistries used across Healthcare and Life Sciences. Management said these products generate more than $700 million in revenues and are high-growth, high-margin and highly regulated.
The project will include two facilities totaling 600,000 square feet. STERIS expects a phased opening in two to three years, beginning with distribution, followed by work transfers from existing chemistry sites in St. Louis, MO, and Plymouth, MN.
STERIS Targets Scale Across Two Core Segments
Healthcare represented 71% of fiscal 2025 revenues, while Life Sciences accounted for 10%. First-quarter fiscal 2027 Healthcare revenues rose 7.6% to $1.05 billion, with consumables up 9.2%. Life Sciences revenues increased 8.6% to $146.7 million, led by 17% growth in capital equipment and 8% growth in consumables.
The project also comes amid active investment across medical technology. Edwards Lifesciences EW reported second-quarter 2026 sales growth of 13.6% to $1.74 billion and raised its full-year constant-currency sales growth outlook. Stryker SYK operates across MedSurg, Neurotechnology and Orthopaedics, underscoring the sector’s broad competitive landscape.
STE Sees Efficiency and Innovation Upside
Management expects the center to expand capacity, accelerate innovation and optimize STERIS’ U.S. chemistries manufacturing and distribution network. Significant automation is planned, which should reduce labor requirements as the operation matures.
The benefits will take time. Management expects the facility to be roughly cost neutral at first, with greater operating leverage emerging as combined volume, automation and scale improve efficiency.
STERIS Sets a Double-Digit ROIC Goal
STERIS expects the project to generate a return on invested capital above 10% within three to five years of opening. That target gives investors a concrete benchmark for judging whether the capital commitment produces sufficient economic returns.
Management expects about $75 million of additional capital spending in fiscal 2027, roughly $350 million in fiscal 2028 and the remaining $175 million in fiscal 2029.
STE Must Manage Spending and Execution Risk
Fiscal 2027 capital expenditures are now expected to be about $450 million, up from the prior $375 million outlook. Free cash flow guidance was reduced to about $800 million from $850 million as higher project spending offsets part of first-quarter cash generation.
STERIS also expects $55 million to $70 million of pretax restructuring charges tied to the consolidation plan. Tariffs, inflation, competition and customer consolidation add pressure, making construction discipline, transition execution and eventual utilization important.
STERIS’ Mixed Scores Keep Expectations Grounded
The chemistry project could strengthen STERIS’ manufacturing base and recurring consumables franchise if the company delivers the planned capacity, efficiency and return benefits. The long lead time and elevated spending mean the financial payoff will depend on execution over several years.
Image Source: Zacks Investment Research
STERIS currently carries a Zacks Rank #3 (Hold). It also has a Value Score of C, a Growth Score of C, a Momentum Score of C and a VGM Score of C. Zacks Style Scores complement the Zacks Rank, with A or B scores generally preferred alongside Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks. STE’s current combination supports a measured stance while investors track the project’s progress.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Research Chief Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
STERIS plc (STE) : Free Stock Analysis Report
Stryker Corporation (SYK) : Free Stock Analysis Report
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
